Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent influenza mrna vaccine mrt5413
- Development stage
- Phase 2
- Lead developer
- Sanofi Pasteur
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Quadrivalent influenza mRNA vaccine MRT5413 is an investigational prophylactic mRNA-based vaccine developed to protect against four different strains of the influenza virus. The vaccine uses messenger RNA (mRNA) technology to encode antigens from the hemagglutinin proteins of selected seasonal influenza viruses. Upon intramuscular injection, the mRNA is delivered into host cells—typically via lipid nanoparticles—where it is translated into viral proteins that stimulate both humoral and cellular immune responses, thereby providing immunity against infection. The primary indication for this vaccine is prevention of seasonal influenza in adults. Clinical trials have evaluated its safety and immunogenicity compared to standard-dose, high-dose, and recombinant quadrivalent influenza vaccines in adults aged 18 years and older[1][2][5][4].
- Other names
- Quadrivalent Influenza mRNA Vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on quadrivalent influenza mrna vaccine mrt5413.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent influenza mrna vaccine mrt5413.